Vaccination 'clear way' of protecting people from Covid-19: Tata group exec

Faster vaccination with more vaccines from wider manufacturers approved with due process, way of making sure that people are safe from Covid-19, according a senior official of the Tata group.

Coronavirus vaccine, Covid-19 vaccine, Covid vaccine
Photo: Shutterstock
Press Trust of India New Delhi
3 min read Last Updated : May 09 2021 | 11:55 AM IST

Faster vaccination of the population, with more vaccines from wider manufacturers approved with due process, is one clear way of making sure that people are safe from COVID-19, according a senior official of the Tata group.

The group is in the process of airlifting 60 cryogenic containers from overseas and building around 400 oxygen generating units that can be used by hospitals in smaller towns to aid combat the devastating second wave of the pandemic. It is also preparing cold chains in case a vaccine requiring low temperature for transportation is approved.

"I would say the faster and sooner we are able to get our people vaccinated, the better it would be because it is one clear way of making sure that our people are safe," Tata Sons President (Infrastructure, Defence, Aerospace and Global Corporate Affairs) Banmali Agrawala told PTI.

Asked if India needs more vaccines from more manufacturers, he said, "Certainly. Whatever it will take for people to be vaccinated faster. But, of course, you have to do it safely. You have to do it after due precaution of whatever is the procedure that the authorities follow in terms of trials."

Agrawala further said, "But yes, if you have wider manufacturers, it makes life that much easier. The more the vaccines, maybe the easier it is to get all our people vaccinated."

Last month, India's drug regulator had granted permission for restricted emergency use of the Russian COVID-19 vaccine Sputnik V with certain conditions, to be imported by Dr Reddy's Laboratories, thus paving the way for a third vaccine to be available in the country.

In January this year, the Drugs Controller General of India (DCGI) had given the emergency use authorisation for two COVID-19 vaccines -- Covaxin of the Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

On the other hand, from May 1, the government allowed vaccination of all persons above the age of 18. Earlier, it was restricted to only those above 45 years of age and frontline COVID warriors.

Stating that the Tata Group is readying itself to aid the vaccination programme, Agrawala said, "We are kind of getting prepared, including if we have a vaccine that needs some cold chain, we are getting prepared with that. Fortunately, within the group, we do have companies like Voltas. So, we are getting prepared."

Stressing on the significance of faster vaccination, he said moving ahead and getting prepared is going to be all about vaccination. "The only way to ensure that we can get back to work in a proper safe manner and go about life is always vaccination."

In the long term, Agrawala said, "There is no denying the fact for us to invest in healthcare infrastructure. It is crucial as a country."

By now, he added, it is pretty clear that the way the economy will grow and develop is directly linked with the country's ability to deal and manage COVID-19.

"If we manage it well, we have got a huge shot. If we are not, then we have got a challenge. It is directly proportional. The two things are linked but I think we can do it," he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineVaccinationVaccineTata group

First Published: May 09 2021 | 11:55 AM IST

Next Story